Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Change in Cash (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Change in Cash data on record, last reported at -$17.4 million in Q3 2025.

  • For Q3 2025, Change in Cash rose 70.25% year-over-year to -$17.4 million; the TTM value through Sep 2025 reached -$19.5 million, up 63.93%, while the annual FY2024 figure was $14.0 million, 117.49% up from the prior year.
  • Change in Cash reached -$17.4 million in Q3 2025 per GOSS's latest filing, down from -$2.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $59.2 million in Q3 2022 and bottomed at -$58.4 million in Q3 2024.
  • Average Change in Cash over 4 years is -$11.6 million, with a median of -$17.4 million recorded in 2025.
  • Peak YoY movement for Change in Cash: soared 270.03% in 2024, then plummeted 352.49% in 2025.
  • A 4-year view of Change in Cash shows it stood at -$41.5 million in 2022, then fell by 21.68% to -$50.5 million in 2023, then skyrocketed by 134.87% to $17.6 million in 2024, then tumbled by 198.67% to -$17.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$17.4 million in Q3 2025, -$2.7 million in Q2 2025, and -$17.1 million in Q1 2025.